about
Transient re-emergence of oil of turpentine allergy in the pottery industry.Sequential treatment of multiple actinic keratoses with solaraze and actikerallNon-melanoma skin cancer.Basal cell carcinoma follow-up practices by dermatologists: a national survey.Efficacy of photodynamic therapy for treatment of basal cell carcinoma in organ transplant recipients.British Association of Dermatologists' guidelines for the management of onychomycosis 2014.Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome.Basal cell carcinoma: from host response and polymorphic variants to tumour suppressor genes.Gliomatosis cerebri or benign intracranial hypertension?Photodynamic therapy for actinic keratosis in organ transplant patients.Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid.Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.Use of photodynamic therapy for treatment of actinic keratoses in organ transplant recipients.Combined effects of gender, skin type and polymorphic genes on clinical phenotype: use of rate of increase in numbers of basal cell carcinomas as a model system.The rate of increase in the numbers of primary sporadic basal cell carcinomas during follow up is associated with age at first presentation.Sequential treatment of giant basal cell carcinomas.Evidence-based treatment for low-risk basal cell carcinoma.Patients with truncal basal cell carcinoma represent a high-risk group.Increasing capacity for skin surveillance in a transplant review clinic.Glutathione S-transferase polymorphisms: influence on susceptibility to cancer.Systemic photodynamic therapy with Photofrin for naevoid basal cell carcinoma syndrome-A pilot study.Associations between UVR exposure and basal cell carcinoma site and histology.Susceptibility to basal cell carcinoma: associations with PTCH polymorphisms.Polymorphism in the nuclear excision repair gene ERCC2/XPD: association between an exon 6-exon 10 haplotype and susceptibility to cutaneous basal cell carcinoma.Glutathione S-transferase GSTP1 and cyclin D1 genotypes: association with numbers of basal cell carcinomas in a patient subgroup at high-risk of multiple tumours.Basal cell carcinoma: genetic homogeneity in a tumour type displaying phenotypic diversity.Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype.Epidermoid cysts mimicking recurrence of superficial basal cell carcinoma following photodynamic therapy.Oral hedgehog-pathway inhibitors for basal-cell carcinoma.PathergyAge-related differences in simultaneous interarm blood pressure measurements.Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases.Angiolymphoid hyperplasia with eosinophilia affecting the penis.Toxicodendron dermatitis in the UK.Extramammary Paget's disease treated with topical and systemic photodynamic therapy.Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene.Infliximab as a treatment for recalcitrant pyoderma gangrenosum.CT scanning and pseudotumour cerebri.Contact sensitivity and systemic reaction to pseudoephedrine and lignocaine.
P50
Q30469689-CE316194-D02D-4EF2-9E66-EA2CBFA5D046Q34023443-75A662B4-F50C-4565-AB11-A9C7190B94D4Q34099783-C51A8CA6-BD2F-4699-869E-354B40F7672CQ34567281-CFB5CE91-4804-40F5-B351-D431CB6CDDC3Q35017520-0FDD0576-014A-48B5-A4FA-1D96DE2D79C9Q35437556-FF4D3F46-03A2-4474-934E-1ABBC2459DDAQ35477995-66A6DDA7-D3CF-4840-A666-C655E67BB278Q36016777-64051FED-D26F-4F94-9B44-99239BF5A4A1Q36680087-299975F1-4E62-4587-8FB4-67A699B6E844Q37965984-EF719354-9A4A-42EF-82D0-F971CEE7126EQ38089086-BC40CA9B-6847-4BCC-89DB-454E9ADB123AQ38203718-07F9D2F8-4960-4BFC-9FA4-E85B08F9FDFCQ38485521-72126EEE-DA1D-4A19-BC91-A4DADCBC30A4Q41481044-25C6CC28-6254-4BA6-A60E-6A1A38A11D53Q42434848-72288EE3-DC0F-41C7-80BB-7C220012E247Q42435293-F1EDF42C-D84C-42DC-B29C-6C3583DF4D79Q42437752-E3382897-B06F-4DD0-8EBF-518E3D26D5CDQ42450864-736E0650-DC9C-4BA7-977F-2F2CAA099137Q42452882-9D4C2D55-638E-4D9C-B19E-36E461729D6CQ42457435-39E77FB6-EF8C-41A2-B268-6D6E32DC5972Q42458723-4395FA2C-BCE5-46CB-A815-2C4A2F88892FQ42462626-EC574D8E-6669-4BA1-878C-8979FD041672Q42470310-84450B4C-E510-443C-BEA0-2B2137476DD7Q42471809-5761B223-706B-4846-A9BC-FC01520D5277Q42475749-4E02D699-41C1-4229-85DC-308E5755D628Q42493017-EBC04150-B24E-4F3C-9710-6752BCE342DFQ42495929-5217ABAB-D97E-4C36-A60A-2E9D9A23ABCDQ42503896-B14A3BCD-5FE6-4040-8286-ACEF819CBCDCQ42504888-08703898-B861-47A6-AE9D-CD82C53C709EQ42507516-A1CB0E86-ADD6-408A-B2C0-FD9EA2D489A5Q42851232-ED0E2A63-939B-49D0-BE40-81419AFA23ADQ43065860-3B443D16-F588-477E-BD22-01B0D34A30AFQ43762900-8B40C5AA-C101-4E4E-B554-069263D8F52FQ46483617-21B6CC3C-89A5-4C4C-A591-577CB4C2B58FQ47592867-D5940E87-D581-453A-80AD-607A65EBAD1DQ47606328-E0A16381-CBC9-454E-8934-46F80519447EQ47704059-6EE4A2D4-D077-48E2-9BDB-AF8E49CD45F0Q48030927-22A4EEB3-2210-4E9E-B323-DED53AB70986Q48104026-EA590887-1175-451E-ADF9-A213D2BABF5BQ51507895-73CA251E-FDC9-4192-B51F-F59A99DA1608
P50
description
researcher, ORCID id # 0000-0002-2969-9922
@en
wetenschapper
@nl
name
John Lear
@ast
John Lear
@en
John Lear
@es
John Lear
@nl
type
label
John Lear
@ast
John Lear
@en
John Lear
@es
John Lear
@nl
prefLabel
John Lear
@ast
John Lear
@en
John Lear
@es
John Lear
@nl
P106
P1153
16747026700
P31
P496
0000-0002-2969-9922